EIM
FPRX

Essex Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Essex Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,692
Closed -$382K – 386
2017
Q2 		$382K Buy
12,692
+2,308
+22% +$72K 0.05% 270
2017
Q1 		$375K Buy
+10,384
New +$458K 0.06% 285

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Essex Investment Management's FPRX Position: Q3 2017 in Review

Essex Investment Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2017, closing a stake of 12,692 shares — an estimated $382K sold.

Essex Investment Management first reported a position in FPRX in Q1 2017 and held it in 2 quarters. The position peaked at $382K in Q2 2017. 126 funds tracked by Wall St. Rank hold FPRX as of Q3 2017.

  • Essex Investment Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Essex Investment Management sold 12,692 Five Prime Therapeutics, Inc. shares in Q3 2017, an estimated $382K.
  • Essex Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2017 and held it in 2 quarters.
  • Essex Investment Management's Five Prime Therapeutics, Inc. position peaked at $382K in Q2 2017.
  • 126 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2017.

Based on Essex Investment Management's 13F filing for Q3 2017, filed 30 Oct 2017.